Lipoprotein-associated Phospholipase A2 and Its Possible Association with COPD Development: a Case-control Study

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2024 Nov 13

PMID 39538218

Authors

He Yu

Ying Yang

Jie Zhou

Mingxia Wu

Zongtao Chen

Affiliations

Soon will be listed here.

Abstract

Background: The association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with various cardiovascular events has been well-established. However, the exploration of its potential involvement in Chronic obstructive pulmonary disease (COPD) is currently limited. Therefore, our study aims to examine the relationship between Lp-PLA2 and pulmonary conditions, including emphysema, obstructive ventilatory dysfunction as well as small airway dysfunction, to provide further evidence of a possible association with COPD development.

Methods: Using data from the Southwest Hospital Health Management Center, spanning January 2013 to July 2024, we analyze relationship of serum Lp-PLA2 levels with diffuse pulmonary emphysema and pulmonary functions. In univariate analysis, group differences were assessed with t-tests for numerical variables and Chi-square tests for categorical data. Variables found to be statistically significant (two-sided P < 0.05) in univariate analysis were subsequently included as covariates in multivariate analysis, performed using a binary logistic regression model. Odds ratios and 95% confidence intervals were calculated to assess the differences.

Results: We established 2 case-control populations: the Imaging population (1056 subjects, mean age 57.666 ± 8.700 years old, 89.9% male) selected from 24,670 initial records, and the Pulmonary Function population (279 subjects, mean age 52.082 ± 11.473 years old, 71.4% male) selected from 1868 initial records. Univariate analysis revealed that serum Lp-PLA2 levels were significantly higher in patients with diffuse pulmonary emphysema, obstructive ventilatory dysfunction as well as small airway dysfunction compared to those without (454.682 ± 141.382U/L vs. 423.330 ± 140.658U/L, P < 0.001; 475.059 ± 157.181U/L vs. 420.824 ± 142.119U/L, P = 0.006; 475.31 ± 148.980U/L vs. 439.036 ± 157.977U/L, P = 0.049, respectively). Multivariate analysis further showed higher Lp-PLA2 levels were associated with increased risks of diffuse pulmonary emphysema, obstructive ventilatory dysfunction as well as small airway dysfunction. Using Lp-PLA2 ≤ 300 U/L as reference, odds ratios for the aforementioned conditions showed a gradually increasing trend with every 100U/L increase in Lp-PLA2 levels.

Conclusions: Our preliminary study suggests that Lp-PLA2 is independently associated with diffuse pulmonary emphysema, obstructive ventilatory dysfunction as well as small airway dysfunction, which are commonly seen in COPD development. These findings indicated a possible association between Lp-PLA2 and COPD, though further validation is needed in a large cohort of COPD patients.

References

Zhao X, Yue Y, Wang X, Zhang Q . Bioinformatics analysis of PLA2G7 as an immune-related biomarker in COPD by promoting expansion and suppressive functions of MDSCs. Int Immunopharmacol. 2023; 120:110399. DOI: 10.1016/j.intimp.2023.110399. View

Ghosh M, Tucker D, Burchett S, Leslie C . Properties of the Group IV phospholipase A2 family. Prog Lipid Res. 2006; 45(6):487-510. DOI: 10.1016/j.plipres.2006.05.003. View

Silva I, Mello A, Damasceno N . Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review. Lipids Health Dis. 2011; 10:170. PMC: 3204246. DOI: 10.1186/1476-511X-10-170. View

Zalewski A, Macphee C . Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005; 25(5):923-31. DOI: 10.1161/01.ATV.0000160551.21962.a7. View

Aprahamian T, Rifkin I, Bonegio R, Hugel B, Freyssinet J, Sato K . Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med. 2004; 199(8):1121-31. PMC: 2211887. DOI: 10.1084/jem.20031557. View

Jiang C, Peng M, Dai Z, Chen Q . Screening of Lipid Metabolism-Related Genes as Diagnostic Indicators in Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2023; 18:2739-2754. PMC: 10693249. DOI: 10.2147/COPD.S428984. View

Nguyen J, Robinson D, Sidhaye V . Why new biology must be uncovered to advance therapeutic strategies for chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2020; 320(1):L1-L11. PMC: 7847061. DOI: 10.1152/ajplung.00367.2020. View

Christenson S, Smith B, Bafadhel M, Putcha N . Chronic obstructive pulmonary disease. Lancet. 2022; 399(10342):2227-2242. DOI: 10.1016/S0140-6736(22)00470-6. View

Tellis C, Tselepis A . The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009; 1791(5):327-38. DOI: 10.1016/j.bbalip.2009.02.015. View

10.

Koo H, Jin K, Kim D, Chung H, Lee C . Association of incidental emphysema with annual lung function decline and future development of airflow limitation. Int J Chron Obstruct Pulmon Dis. 2016; 11:161-6. PMC: 4745855. DOI: 10.2147/COPD.S96809. View

11.

Deng M, Yin Y, Zhang Q, Zhou X, Hou G . Identification of Inflammation-Related Biomarker Lp-PLA2 for Patients With COPD by Comprehensive Analysis. Front Immunol. 2021; 12:670971. PMC: 8176901. DOI: 10.3389/fimmu.2021.670971. View

12.

Matsunaga K, Harada M, Suizu J, Oishi K, Asami-Noyama M, Hirano T . Comorbid Conditions in Chronic Obstructive Pulmonary Disease: Potential Therapeutic Targets for Unmet Needs. J Clin Med. 2020; 9(10). PMC: 7598716. DOI: 10.3390/jcm9103078. View

13.

Bhatt S, Soler X, Wang X, Murray S, Anzueto A, Beaty T . Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016; 194(2):178-84. PMC: 5003216. DOI: 10.1164/rccm.201511-2219OC. View

14.

Packard C, OReilly D, Caslake M, McMahon A, Ford I, Cooney J . Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000; 343(16):1148-55. DOI: 10.1056/NEJM200010193431603. View

15.

Kabarowski J . G2A and LPC: regulatory functions in immunity. Prostaglandins Other Lipid Mediat. 2009; 89(3-4):73-81. PMC: 2740801. DOI: 10.1016/j.prostaglandins.2009.04.007. View

16.

Davidson M, Corson M, Alberts M, Anderson J, Gorelick P, Jones P . Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008; 101(12A):51F-57F. DOI: 10.1016/j.amjcard.2008.04.019. View

17.

Sudhir K . Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab. 2005; 90(5):3100-5. DOI: 10.1210/jc.2004-2027. View

18.

Bohadana A, Teculescu D, Martinet Y . Mechanisms of chronic airway obstruction in smokers. Respir Med. 2004; 98(2):139-51. DOI: 10.1016/j.rmed.2003.09.005. View

19.

Mallat Z, Lambeau G, Tedgui A . Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers. Circulation. 2010; 122(21):2183-200. DOI: 10.1161/CIRCULATIONAHA.110.936393. View

20.

Colley K, Wolfert R, Cobble M . Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. 2011; 2(1):27-38. PMC: 3084931. DOI: 10.1007/s13167-011-0063-4. View